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Background. Recent studies have shown that OCT-measured retinal nerve ﬁber layer (RNFL) values may represent a marker for
axonal damage in the anterior visual pathway of optic neuritis (ON) and multiple sclerosis (MS) patients. The goal of this study
was to determine the link between RNFL values and initial magnetic resonance imaging (MRI) evidence of central nervous system
(CNS) inﬂammation in patients with acute ON. Methods. Fifty patients who experienced ON as a clinically isolated syndrome
(CIS)werefollowedforameanperiodof34monthswithOCTtesting.RNFLvaluesinaﬀected(ON)eyesandclinicallyunaﬀected
(non-ON) eyes were compared between patients with MRI evidence of white matter lesions and those with normal baseline MRI
ﬁndings, over a two year period. Findings. Twenty-one patients (42%) developed clinically deﬁnite MS (CDMS) during the study.
After two years, temporal RNFL values were thinner (P = .07) in ON patients with MRI lesions at baseline, but the results were
not signiﬁcant. Conclusions. There is no association between RNFL values and baseline MRI status in ON patients at risk for future
CDMS over a two year period.
1.Introduction
Optic neuritis (ON) is an inﬂammatory optic nerve injury,
which is strongly associated with multiple sclerosis (MS)
[1–11]. Approximately 20% of MS patients present with
ON as their ﬁrst demyelinating event, and 30 to 70% of
MS patients develop ON during the course of their disease
[2, 7]. The longitudinal followup from the optic neuritis
treatment trial [3] (ONTT) demonstrated that the initial
magnetic resonance imaging (MRI) study is the most potent
predictor for future MS after acute ON: such that evidence
of disseminated central nervous system (CNS) inﬂammation
on baseline MRI increases the risk for future clinically
deﬁnite MS (CDMS) after acute ON [4–6]. After 15 years
72% of ON patients with one or more white matter lesions
on their initial MRI developed CDMS, as compared to 25%
of patients with no MRI lesions [6]. The administration
of high-dose corticosteroids has been shown to delay the
conversion to MS for up to two years after ON, but not
thereafter [8]. Early initiation of disease-modifying therapies
delays the development of MS in patients with ON and other
clinically isolated syndromes (CISs) [9–11].
The evidence supporting early initiation of disease-
modifying therapy in patients at risk for MS is robust [9–11],
as is the need to develop eﬀective, cost-eﬀective strategies to
capture disease activity and monitor therapeutic eﬀects in
these patients. One tool which has emerged as a potential
structural marker for axonal loss in MS patients is optical
coherence tomography (OCT) [7, 12–25]. This noninvasive
ocular imaging technology employs low-coherence interfer-
ometry to generate high-resolution [<10 microns (µm)],
cross-sectional images of the retinal nerve ﬁber layer (RNFL)
by measuring the backscatter of infrared light [26, 27]. The
RNFL contains the retinal ganglion cell axons that comprise
the optic nerve; and because it lacks myelin, represents a
unique region of the central nervous system. Changes in2 Multiple Sclerosis International
RNFL thickness after ON have been interpreted to reﬂect
initial axoplasmic ﬂow stasis and subsequent attrition caused
by inﬂammation in the anterior visual pathway. Recent
studies have shown that OCT-measured RNFL values are
reduced after ON [12–16, 25] and that the extent of RNFL
atrophy correlates with diminished scores of visual and
neurological function [12–16, 19, 21, 24, 25]M R Im e a s u r e s
ofopticnerveandbrainatrophy[17–20],anddiseaseactivity
in MS patients [19]. To date, an association between RNFL
thickness and initial MRI status in ON patients at risk of
developing MS has not been established. Thus, the primary
objectiveofthisstudywastodeterminewhetherRNFLvalues
diﬀered between ON patients with evidence of clinically
silent brain lesions on initial MRI and patients with no
MRI evidence of CNS inﬂammation over a two-year period.
Our second aim was to compare RNFL values between
patients treated with high-dose corticosteroid therapy and
untreated patients, to ascertain whether RNFL diﬀerences
distinguished the two groups.
2. Methods
2.1. Study Design and Sampling. This was a prospective coh-
ort study of consecutively sampled patients referred to the
Ottawa Hospital Neuro-Ophthalmology Clinic for the evalu-
ation of acute ON between January 2003 and June 2007. The
study received approval by the local ethics committee at this
institution, and participating patients provided informed
written consent.
2.2. Inclusion and Exclusion Criteria. Fifty CIS patients who
experienced a single, unilateral ON event were included
in the study. Patients were diagnosed with ON if they
demonstratedthefollowingclinicalfeatures:decreasedvisual
acuity, a visual ﬁeld defect, which followed the topography of
the RNFL, a relative aﬀerent pupil defect, and a compatible
fundus examination (mild or no optic disc edema and the
absence of pallor at the time of the acute event). Exclusion
criteria included other established causes of vision loss in the
aﬀected eye (amblyopia, glaucoma, and dense cataracts), a
known diagnosis of MS or neuromyelitis optica (NMO), and
inability to undergo reliable OCT testing.
Other Variables. Demographic and clinical variables includ-
ing age, gender, the presence of pain, mono-focal (ON
without other neurological symptoms) versus multi-focal
ON (associated with neurological symptoms referable to
a region of the CNS diﬀerent from the anterior visual
pathway) as a CIS presentation, and the initiation of disease-
modifying disease (DMD) therapy were recorded. The time
tobaselineMRIacquisitionandMRIprotocolsvariedamong
patients. For this reason, we were not able to employ
the revised McDonald criteria [28] to deﬁne radiologi-
cal conversion to MS after ON Instead, we documented
whether patients had MRI evidence of clinically silent lesions
representing CNS inﬂammation at the time of the ON
event [9]. All MRI results were interpreted by qualiﬁed
neuroradiologists at the University of Ottawa. Speciﬁc MS
MRI protocols were employed (1.5T GE scanners), which
included (coronal, axial, and sagittal imaging) T1-weighted,
T2-weighted, and FLAIR sequences, either with or without
gadolinium. The treating physician employed individualized
discretionregardingthedecisiontoadministercorticosteroid
therapy for acute management of ON. Patients who received
corticosteroid therapy were treated within two weeks of
the ON event with the equivalent of 1000mg intravenous
methylprednisolone daily for three days. Disease-modifying
therapieswereadministered to aminority (12/50) ofpatients
during the course of this study. No patients initiated disease-
modifying therapy earlier than 6 months after ON. The
limited number of CIS patients who received disease-
modifying agents precluded eﬀorts to compare the eﬀects of
disease-modifying therapy on RNFL values after ON.
2.3. Clinical Assessment. Patients were followed with repeat
visual and OCT testing for a minimum of 24 months.
The neuroophthalmic assessment included best-corrected
Snellen visual acuity, visual ﬁeld analysis, and dilated
ophthalmoscopy. Neurological evaluations were performed
at 6-month intervals by a neurologist at the MS Clinic at
the Ottawa Hospital. Patients aged greater than 45 years or
those with atypical features (including incomplete recovery
after ON) also underwent visual electrodiagnostic testing
(including pattern visual evoked potential (VEP) and multi-
focal electroretinogram studies) to exclude retinal mimics
of ON. If clinically indicated, additional studies were also
performed to exclude conditions that could mimic MS such
as myeloproliferative disorders, NMO, syphilis, sarcoidosis,
or Lyme disease.
2.4. Optical Coherence Tomography. The OCT (Stratus ver-
sion 3; OCT 4 Software, Zeiss Meditech, Dublin, Calif, USA)
system was used to obtain circular peripapillary scans (Fast
RNFL protocol), which included a set of three 3.4mm diam-
eter retinal scans averaged to provide the RNFL thickness
at 256 points along the circumference of the circular scan
in each eye after mydriasis with 1% tropicamide. The OCT
software employed an automated computerized algorithm to
calculate the average thickness of the RNFL and to compare
these measurements to a normative database of age-matched
controls, for patients aged 18 years or older. A trained
ophthalmic medical technologist performed all OCT testing
and monitored scans to ensure that ﬁxation was reliable.
OCT scans with signal strength equal to or greater than 7
(out of 10) were included in the study.
2.5. Outcome Measures and Statistical Analysis. The primary
outcomemeasuresinthisstudywereRNFLvaluesinONeyes
and non-ON eyes, which were compared between patients
with clinically silent lesions on their baseline MRI scan and
patients with no baseline evidence of CNS inﬂammation.
As a secondary outcome measure, we compared RNFL
valuesbetweenpatientstreatedwithhigh-dosecorticosteroid
therapy for acute ON and untreated patients. Continuous
variableswereﬁrstcheckedfornormality,andthensummary
statistics were calculated and reported. Median and rangeMultiple Sclerosis International 3
Table 1: Demographic and clinical characteristics among optic
neuritis patients.
Demographics/characteristics
Number of patients 50
Mean age in years (range) 34 (18–50)
Male: female‡ 10:40
CIS∗:C D M S † 29: 21
Pain (%) 42/50 (84)
Mono-focal§: Multi-focal (%) 18:32
Abnormal MRI# (%) 32/50 (64)
Abnormal CSF∗∗ (%) 14/20 (70)
Corticosteroids∧ (%) 25/50 (50)
‡Ratio of male to female patients included in the study; ratio of ∗ clinically
isolated syndrome patients to †clinically deﬁnite MS patients; number
of patients presenting with §mono-focal versus multi-focal optic neuritis
as a CIS at baseline; 10#number and percentage of abnormal magnetic
resonance imaging scans at presentation; 9∗∗ number and percentage of
patients with positive oligoclonal bands in their cerebrospinal ﬂuid analysis
at baseline:number and percentage of patients who received treatment
with the equivalent of 1000mg intravenous methylprednisolone for three
days for acute optic neuritis.
were computed for continuous variables that demonstrated
a non-Gaussian distribution, including counts and percent-
ages for categorical variables. For group comparisons, either
the Student’s t-test or the Kruskal-Wallis rank sum test was
used depending on the variable’s distribution attribute. The
entire statistical analysis was performed using STATA (v. 9,
College Station, Tex, USA).
3. Results
3.1. Demographics and Clinical Presentation. Fifty patients
(100 eyes) were included in the study. The mean age was 34
years, and the mean follow-up period was 34 months (range
24–44 months). All patients were followed for a minimum
of 24 months. Twenty-one patients (42%) developed CDMS
during the course of the study, with a mean conversion time
of 27 months. The baseline demographics and clinical data
are included in Table 1.
3.2. Comparing Baseline MRI Status, Treatment with High-
Dose Corticosteroids, and RNFL Thickness. ON Eyes:T h e
presence or absence of disseminated white matter lesions on
the baseline cranial MRI scan in patients was not associated
with signiﬁcant diﬀerences in RNFL thickness a year after
ON. By the second year of followup, temporal RNFL values
(49.8µm) were thinner (P = .07) in patients with abnormal
baseline MRI scans, but the results did not statistically sig-
niﬁcant (Table 2). RNFL values were not signiﬁcantly diﬀer
between patients treated with high-dose corticosteroid ther-
apyanduntreatedpatients foruptotwoyearsafteracuteON
(Table 2). Non-ON Eyes RNFL values did not diﬀer between
patients with clinically silent lesions on initial MRI and
patients without initial MRI evidence of CNS inﬂammation
for up to two years (Table 3). Similarly, treatment with high-
dose corticosteroid therapy, or the lack thereof, was not asso-
ciated with any signiﬁcant diﬀerences in RNFL thickness for
non-ON eyes at year one or year two of followup (Table 3).
4. Discussion
In the current study, we observed no association between
the presence of clinically silent lesions on baseline MRI
and RNFL thickness in CIS patients followed for two years
after an acute ON event. By the second year of followup,
temporal RNFL values were thinner in ON-eyes of patients
with abnormal baseline MRI scans, yet diﬀerences did not
reach statistical signiﬁcance (P = .07). One explanation for
this observation is that there is discordance between OCT-
measured axonal damage and MRI evidence of disseminated
CNS inﬂammation in CIS patients. Conventional MRI
protocols may reﬂect inﬂammatory activity in lieu of axonal
pathology, particularly at the earliest stage of MS. Given
that more robust correlations have been noted between
RNFL atrophy in the anterior visual pathway and MRI
measures of brain volume and atrophy [17, 19, 20], diﬀusion
tensor imaging [29, 30], and magnetic transfer ratios [18],
there may be a stronger correlation between OCT outcomes
and evolving MRI protocols that are speciﬁcally aimed at
capturing axonal attrition in the CNS.
There were no diﬀerences in RNFL atrophy noted
between patients treated with high-dose corticosteroids for
acute ON and untreated patients in this study. It is notewor-
thy that we did not randomize ON patients into treatment
protocols. It is therefore possible that there was some bias
on the part of the treating physician that inﬂuenced the
decision to administer or withhold treatment, which may
have aﬀected our results, Yet, the administration of high-
dose corticosteroids does not impact visual recovery after
ON or future risk of MS in the long term [8]; therefore,
another potential explanation for our ﬁndings is that RNFL
atrophy after acute ON is not signiﬁcantly impacted by acute
management with corticosteroid therapy.
Only two prior reports have explored whether OCT-
measured RNFL values distinguish patients at future risk
of CDMS after ON, and in both studies the results were
predominantly negative [31, 32]P r e v i o u s l y ,w ec o m p a r e d
RNFL values in ON eyes and non-ON eyes between patients
who developed CDMS (42%) and those that did not develop
MS within a minimum of 24 months after an acute ON
event (58%), in the same patient cohort. [31]M e a nR N F L
values were reduced in ON eyes of non-MS patients as
compared to CDMS ON eyes after one year (P = .05) due to
more severe ON events in the former [31]. Temporal RNFL
values were lower in the non-ON eyes of CDMS patients,
but the results were not statistically signiﬁcant (P = .13)
[31]. From our ﬁndings, we concluded that RNFL thickness
did not diﬀerentiate patients at higher risk of converting to
C D M Sa f t e rO N[ 31]. Similarly, Outteryck and colleagues
[32] recently performed OCT testing on 56 CIS patients
(18 with optic neuritis and 38 without optic neuritis) and
32 control subjects, to investigate whether RNFL thickness
and macular volume revealed early retinal axonal loss. In
this prospective case series there was no link between RNFL4 Multiple Sclerosis International
Table 2: Comparing MRI status, corticosteroid therapy, and RNFL∗ values in optic-neuritis-aﬀected eyes.
RNFL ON Eyes∗ Year 1
P value
Year 2
P-value MRI+§ (n = 32) MRI−|| (n = 18) MRI+ (n = 32) MRI− (n = 18)
Overall (SD)¶ 84.4 (17.3) 80.1 (21.1) .45 80.9 (16.6) 85.8 (21.6) .36
Superior 110.8 (22.3) 102.9 (31.9) .32 106.4 (21.6) 106.6 (29.6) .98
Inferior 106.3 (25.0) 95.8 (28.7) .20 99.3 (29.2) 107.9 (33.0) .35
Nasal 68.1 (19.8) 67.1 (21.7) .87 67.3 (16.5) 70.1 (21.0) .61
Temporal 52.4 (17.5) 53.9 (15.2) .78 49.8 (14.2) 58.5 (18.7) .07
Steroid#
(n = 25)
Untreated∗∗
(n = 25) Steroid (n = 25) Untreated
(n = 25)
Overall (SD) 81.4 (15.8) 84.3 (21.4) .59 81.8 (18.6) 83.4 (18.7) .77
Superior 104.7 (22.2) 111.4 (29.7) .38 104.5 (23.5) 108.5 (25.7) .57
Inferior 100.7 (22.2) 104.5 (30.5) .63 102.1 (31.3) 102.8 (30.5) .94
Nasal 70.5 (21.7) 65.2 (18.6) .37 67.8 (18.9) 68.8 (17.6) .85
Temporal 49.5 (14.9) 56.2 (17.7) .16 52.3 (15.4) 53.3 (17.5) .88
∗Retinal nerve ﬁber layer thickness (µm); §baseline magnetic resonance imaging evidence of clinically silent inﬂammation [8]; ||normal baseline magnetic
resonance imaging scan; ¶mean overall RNFL values (standard deviation) and mean RNFL values in the superior, inferior, nasal, and temporal quadrants;
#patients treated with the equivalent of 1000mg of intravenous methylprednisolone for acute management of optic neuritis; ∗∗patients not treated acutely
for optic neuritis.
Table 3: Comparing MRI status, corticosteroid therapy, and RNFL∗ values in nonaﬀected eyes.
RNFL Non-ON
Eyes∗
Year 1
P value
Year 2
P value MRI+§ (n = 32) MRI−|| (n = 18) MRI+ (n = 32) MRI− (n = 18)
Overall (SD)¶ 103.9 (10.5) 102.2 (9.4) .56 104.1 (12.2) 104.3 (9.9) .94
Superior 131.1 (15.6) 132.9 (13.0) .67 134.4 (20.6) 135.3 (13.6) .87
Inferior 134.0 (16.9) 125.4 (12.7) .07 131.0 (17.9) 127 (14.9) .42
Nasal 84.3 (17.0) 80.4 (17.7) .46 84.0 (18.0) 84.7 (21.4) .89
Temporal 66.3 (13.0) 70.0 (10.1) .30 66.9 (13.6) 70.7 (13.8) .34
Steroid#
(n = 25)
Untreated∗∗
(n = 25) Steroid (n = 25) Untreated
(n = 25)
Overall (SD) 103.6 (9.3) 103.0 (11.0) .84 104.7 (10.5) 103.6 (12.5) .75
Superior 130.7 (12.4) 132.8 (16.7) .63 136.0 (14.7) 133.5 (21.4) .63
Inferior 131.4 (14.2) 130.5 (17.8) .85 130.2 (17.8) 129.0 (16.2) .80
Nasal 85.8 (18.6) 80.0 (15.5) .23 82.8 (19.8) 85.7 (18.6) .60
Temporal 66.6 (11.2) 68.6 (13.0) .56 69.7 (13.8) 66.8 (13.7) .47
∗Retinal nerve ﬁber layer thickness (µm); §Abnormal baseline magnetic resonance imaging study [8]; ||Normal baseline magnetic resonance imaging study;
¶Mean overall RNFL value (standard deviation), and mean RNFL values in the superior, inferior, nasal and temporal quadrants; #Patients treated with the
equivalent of 1000mg of intravenous methyl-prednisolone for acute management of optic neuritis; ∗∗Patients not treated acutely for optic neuritis.
atrophy and dissemination of CNS inﬂammatory lesions on
the initial MRI, gadolinium enhancement on baseline MRI,
multifocal presentation, abnormal visual evoked potentials,
or the development of Mc-Donald proven MS at 6-months
[32]. Furthermore-patients who developed CDMS (n = 13)
orMcDonaldcriteria-provenMS(n = 23)didnothavemore
severe RNFL atrophy [32]. These investigators concluded
thatOCTdoesnotdemonstrateretinalatrophyattheearliest
clinical stage of MS, nor does it predict conversion to MS at
6 months in CIS patients [32].
There were a number of shortcomings in our study,
whichmayhaveimpactedourresults.Firstandforemost,our
patient population was quite limited, which likely hindered
the statistical power of our comparisons. Second, we used
clinical criteria [33] and not radiological criteria [28]t o
conﬁrmthediagnosisofMS,whichmayhavediminishedour
sensitivitytodetectthediagnosisofMSinsomeCISpatients.
Third, we did not randomize ON patients into treatment
protocols, and it is therefore possible that patients who
received corticosteroids were treated due to some bias on the
part of the treating physician. Fourth, the two-year followup
period may have been insuﬃcient to detect signiﬁcant RNFL
diﬀerences between ON patients with disseminated CNS
inﬂammation on initial MRI and those without clinically
silent MRI results at baseline. Therefore, further study is
needed to determine the predictive value of RNFL thicknessMultiple Sclerosis International 5
in ON patients at risk of future MS and to establish the role
of OCT in the earliest phases of this disease. Future clinical
trials should include larger patient cohorts and potentially
employ novel MRI strategies, which are sensitive to the early
detection of axonal attrition in MS.
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